Hypothalamic inflammation plays a pivotal role in appetite dysregulation across various pathological conditions, including cancer cachexia. However, delivering anti-inflammatory agents to microglia, key mediators of hypothalamic inflammation, remains challenging due to the unsurmountable blood-brain barrier (BBB). To overcome this challenge,...
Around 80% of patients with advanced cancer have cancer cachexia (CC), a serious complication for which there are currently no FDA-approved treatments. Nuciferine (NF) is the main active ingredient of lotus leaf, which has anti-inflammatory, anti-tumour and other effects. The...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high-risk cancer population with mortality risk explained by cGVHD severity, but also...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Cachexia is a complex syndrome that impacts up to half of patients with cancer. Criteria systems have been developed for the purpose of diagnosing and grading cachexia severity in clinical settings. One of the most widely known is those developed...
The Global Leadership Initiative on Malnutrition (GLIM) criteria provide a framework for evaluating cachexia in cancer patients, yet variability in diagnostic application hinders its use. The aim of the present study was to examine the prevalence and prognostic value of...
Cachexia (disease-related wasting) is a complex metabolic syndrome which occurs in people with chronic illnesses, including cancer, HIV/AIDS, kidney disease, heart disease, and chronic obstructive pulmonary disease (COPD). People with cachexia experience unintentional weight loss, muscle loss, fatigue, loss of...
๐๏ธ 2025-03-25
๐ฐ Publication: Cochrane Database Of Systematic Reviews
The existing diagnostic criteria for cancer cachexia do not meet clinical needs. We aimed to establish novel comprehensive evaluation scales for cachexia specific to patients with solid tumours. This study included 12โ651 patients (males: 6793 [53.7%]; females: 5858 [46.3%]; medium...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
In patients receiving anti-cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This review examines oncological endpoints in CC clinical trials. An electronic literature...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Accurate toxicity reporting in cancer clinical trials is necessary to promote regulatory decision making. Up to 85% of those with some cancers (e.g., oesophagus, head and neck, and pancreas) experience significant progressive weight loss (WL) throughout treatment. Therefore, it is...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Numerous studies support the association of exercise training, physical activity (PA) and sedentary behaviour (SB) with both mortality and morbidity outcomes. The results across studies have been inconsistent, and no umbrella reviews have yet been conducted on this topic. We...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Cancer cachexia has substantial impacts on people's quality of life. There is no current gold standard treatment, but the complex pathophysiology of cachexia suggests that a multitargeted and individualised treatment approach is needed. We aimed to evaluate the extent to...
๐๏ธ 2025-04-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Cancer cachexia presents a significant challenge, but the ghrelin agonist anamorelin shows promise as a potential treatment. This study examined whether the baseline systemic inflammatory response (SIR) (measured by the modified Glasgow Prognostic Score [mGPS]), low BMI or greater weight...
๐๏ธ 2025-02-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Cachexia is a clinically challenging multifactorial and multi-organ syndrome, associated with poor outcome in cancer patients, and characterised by inflammation, wasting and loss of appetite. The syndrome leads to central nervous system (CNS) function dysregulation and to neuroinflammation; nevertheless, the...
๐๏ธ 2025-02-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Fibroblast activation protein (FAP) is prominently involved in the tumour microenvironment and tissue remodelling processes in most cancers, and its expression is also noted in normal skeletal muscle. This study aims to explore the relationship between FAP expression and age-related...
๐๏ธ 2025-02-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Stay Informed with the Latest Updates and Exclusive Insights!
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
